» Articles » PMID: 22068435

2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Citing Articles

Contribution of hypoxia-inducible factor 1alpha to pathogenesis of sarcomeric hypertrophic cardiomyopathy.

Raj Murthi S, Petry A, Shashikadze B, Stockl J, Schmid M, Santamaria G Sci Rep. 2025; 15(1):2132.

PMID: 39820339 PMC: 11739497. DOI: 10.1038/s41598-025-85187-9.


Hypertrophic Cardiomyopathy as a Form of Heart Failure with Preserved Ejection Fraction: Diagnosis, Drugs, and Procedures.

Banthiya S, Check L, Atkins J US Cardiol. 2024; 18:e17.

PMID: 39508003 PMC: 11539043. DOI: 10.15420/usc.2023.21.


Safety and Effectiveness of Mavacamten Use in Hypertrophic Obstructive Cardiomyopathy: A Systematic Review and Meta-Analysis.

Alharbi T, Alnadawi H, Almutairi G, Altheyab F, Aldoweesh O, Alfehaid O Cureus. 2024; 16(9):e70550.

PMID: 39479079 PMC: 11524545. DOI: 10.7759/cureus.70550.


Oral anticoagulation in patients with hypertrophic cardiomyopathy and non-valvular atrial fibrillation in Japan.

Kitaoka H, Carroll R, Eugene N, Casaes Teixeira B, Matsuo Y, Kubo T ESC Heart Fail. 2024; 12(1):326-337.

PMID: 39300752 PMC: 11769629. DOI: 10.1002/ehf2.15039.


Clinical Characteristics and Outcomes in Patients With Apical and Nonapical Hypertrophic Cardiomyopathy.

Chen Q, Zou J, Katsouras C, You S, Zhou J, Ge H J Am Heart Assoc. 2024; 13(19):e036663.

PMID: 39291501 PMC: 11681465. DOI: 10.1161/JAHA.124.036663.